Company Overview and News

Harrisons Malayalam gets a new CEO

2018-10-08 thehindubusinessline
Venkitraman Anand has been appointed as the Wholetime Director and Chief Executive of Harrisons Malayalam Limited (SBU-A) with effect from October 1. He has an experience of over 34 years and has worked in plantations across Assam, West Bengal, Tamil Nadu and Kerala. Venkitraman started his career in Rungamattee Tea & Industries Limited and worked there for around 12 years and later was associated with Parry Agro Industries Limited, the plantation arm of the Murugappa group, for 17 years.

Monsoon rain threatens output of plantation crops in the South

2018-06-18 thehindubusinessline
The South West monsoon has taken a heavy toll on Kerala's plantation sector, impacting various commodities such as tea, cardamom, pepper and coffee over the last fortnight.

Stop rubber dumping; set import price, says industry

2018-05-21 thehindubusinessline
Minimum import price on rubber is needed to avoid dumping, say stakeholders citing a serious drop in production triggered by imports and low prices.

Harrisons Malayalam bags 5 awards at TGLIA

2018-04-26 thehindubusinessline
Harrison Malayalam Ltd bagged five awards in the 13th edition of ‘The Golden Leaf India Awards’ (TGLIA). The final screening was done in Dubai by a panel of international tea tasters from the buying community.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...